PIM
ALXN

Partner Investment Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Partner Investment Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$911K Sell
8,421
-13,715
-62% -$1.47M 6.54% 2
2019
Q3 		$2.17M Buy
+22,136
New +$2.5M 3.71% 5
2017
Q1 		– Sell
-3,801
Closed -$465K – 123
2016
Q4 		$465K Buy
+3,801
New +$465K 0.62% 53
2015
Q1 		– Sell
-4,113
Closed -$761K – 104
2014
Q4 		$761K Buy
+4,113
New +$762K 0.31% 56

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Partner Investment Management's ALXN Position: Q4 2019 in Review

Partner Investment Management reduced its Alexion Pharmaceuticals (ALXN) stake by 62% in Q4 2019, selling an estimated $1.47M and leaving 8,421 shares worth $911K. The position accounts for 6.54% of the portfolio, ranked #2.

Partner Investment Management first reported a position in ALXN in Q4 2014 and has held it in 4 quarters since. The position peaked at $2.17M in Q3 2019. 669 funds tracked by Wall St. Rank hold ALXN as of Q4 2019.

  • Partner Investment Management held 8,421 shares of Alexion Pharmaceuticals worth $911K as of Q4 2019.
  • Partner Investment Management sold 13,715 Alexion Pharmaceuticals shares in Q4 2019, an estimated $1.47M.
  • Alexion Pharmaceuticals made up 6.54% of Partner Investment Management's portfolio in Q4 2019, its #2 holding.
  • Partner Investment Management first reported a position in Alexion Pharmaceuticals in Q4 2014 and has held it in 4 quarters since.
  • Partner Investment Management's Alexion Pharmaceuticals position peaked at $2.17M in Q3 2019.
  • 669 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2019.

Based on Partner Investment Management's 13F filing for Q4 2019, filed 14 Feb 2020.